|Bid||14.37 x 3400|
|Ask||14.39 x 1100|
|Day's range||14.17 - 14.54|
|52-week range||8.31 - 32.74|
|PE ratio (TTM)||-3.56|
|Dividend & yield||0.00 (0.00%)|
|1y target est||N/A|
Shares of Valeant Pharmaceuticals International plunged Tuesday following news that activist investor Bill Ackman exited the controversial drug company. Shares of the Canadian company dived 10.9 percent to $10.80 by midday after an announcement that Ackman's hedge fund, Pershing Square Capital Management, sold its investment in the drug firm at a loss. In addition, Ackman and fellow Pershing executive Stephen Fraidin said they would step down from the Valeant board.
New York, United States, Jan 11, 2017 - (ABN Newswire) - (NetworkNewsWire) Jaguar Animal Health, Inc. (NAS:JAGX - News), a company in the business of developing and commercializing gastrointestinal products for companion animals, horses, and production animals, recently had its company outlook updated by Aegis Capital Corp. (http://nnw.fm/8Jn4H). The company update was announced after JAGX made several decisions that Aegis believes could improve the outlook for the company. The company, which is committed to identifying animal health market opportunities to develop products specific to various species, announced that it has proposed a business combination with its parent company, Napo Therapeutics, Inc., to form a single entity.
LAVAL, Quebec, Jan. 4, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ('Valeant') today announced that the Board of Directors has elected Richard (Dick) U. DeSchutter ...